Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.

abstract：:The usual drugs for migraine attacks carry risks of increased frequency, resistance to other treatment, drug dependency, and abuse. Ergotamines may also be vascular risk factors. Alternative drugs without these risks would be useful. Flunarizine could be an alternative. Migraine cannot be reduced to molecular pathophy...

journal_title：Journal of cardiovascular pharmacology

authors： Isler H

更新日期：1991-01-01 00:00:00

abstract：:Bucindolol is a nonselective beta-adrenergic receptor antagonist that has additional vasodilating properties. Because some beta-adrenergic receptor antagonists such as cyanopindolol are used as 5-HT1A/5-HT1B receptor antagonists, we tested the hypothesis that bucindolol can interact with 5-HT receptors. Both in vitro ...

journal_title：Journal of cardiovascular pharmacology

authors： Watts SW,Fink GD,Silver PJ,Cushing DJ

更新日期：2000-01-01 00:00:00

abstract：:Vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions. Vascular smooth muscle, however, does not represent a homogeneous tissue. Using myosin as a marker of the differentiation processes in development and in vascular disease, we have been able to demonstrate the existence o...

journal_title：Journal of cardiovascular pharmacology

authors： Pauletto P,Sartore S,Giuriato L,Scatena M,Tonello M,Scannapieco G,Pessina AC,Dal Palù C

更新日期：1992-01-01 00:00:00

abstract：:The complex formed between endothelin (ET) and its binding protein was adequately stable to be separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) at low temperature. Cross-linking was not necessary. This simple method was applied for both qualitative (determination of molecular weight ...

journal_title：Journal of cardiovascular pharmacology

authors： Takasuka T,Satoh N,Horii I,Furuichi Y,Watanabe T

更新日期：1991-01-01 00:00:00

abstract：AIMS:To determine whether short-term treatment with trimetazidine (TMZ), an antiischemic agent that directly inhibits fatty acid oxidation and results in stimulation of glucose oxidation, may improve myocardial perfusion and left ventricular systolic function in diabetic patients with ischemic cardiomyopathy. METHODS ...

journal_title：Journal of cardiovascular pharmacology

authors： Belardinelli R,Cianci G,Gigli M,Mazzanti M,Lacalaprice F

更新日期：2008-06-01 00:00:00

abstract：:The CARTAGOMAX study assessed the safety and efficacy of bivalirudin during real-world cardiac intervention. This was a single-center prospective study. Patients with acute coronary syndrome undergoing percutaneous coronary intervention were anticoagulated with bivalirudin alone or unfractionated heparin plus a glycop...

journal_title：Journal of cardiovascular pharmacology

authors： Cascón-Pérez JD,Abellán-Huerta J,Giner-Caro JA,Dau-Villareal DF,Mármol-Lozano R,Jaulent-Huertas L,Bonilla-Pacheco YI,Ruiz-Abellón Mdel C,Picó-Aracil F,Castillo-Moreno JA

更新日期：2016-09-01 00:00:00

abstract：:Myocardial infarction (MI) is one of cardiovascular diseases with high incidence and mortality. MicroRNAs, as posttranscriptional regulators of genes, are involved in many diseases, including cardiovascular diseases. The aim of the present study was to determine whether miR-203 was functional in MI therapy and how it ...

journal_title：Journal of cardiovascular pharmacology

authors： Zhang J,Pan J,Yang M,Jin X,Feng J,Wang A,Chen Z

更新日期：2019-11-01 00:00:00

abstract：:Carvedilol is a dual-acting drug designed to produce two complementary effects: beta-blockade and vasodilation. These effects are induced in the same dose range, a prerequisite for utilizing both properties in an appropriate manner. The vasodilation is mediated predominantly by specific alpha 1-adrenoceptor blockade. ...

journal_title：Journal of cardiovascular pharmacology

authors： Sponer G,Strein K,Bartsch W,Müller-Beckmann B

更新日期：1992-01-01 00:00:00

abstract：:Cilostazol, a potent phosphodiesterase 3 inhibitor and anti-thrombotic agent, was recently shown to inhibit adenosine uptake into cardiac myocytes and vascular cells. In the present studies, cilostazol inhibited [ H]-adenosine uptake in both platelets and erythrocytes with a median inhibitory concentration (IC ) of 7 ...

journal_title：Journal of cardiovascular pharmacology

authors： Sun B,Le SN,Lin S,Fong M,Guertin M,Liu Y,Tandon NN,Yoshitake M,Kambayashi J

更新日期：2002-10-01 00:00:00

abstract：:The effects of angiotensin-converting enzyme inhibitor captopril on infarct size and cardiovascular hemodynamics were studied in 35 conscious dogs subjected to 24 h of coronary occlusion. Following occlusion of the left anterior descending coronary artery, 10 dogs were infused with captopril 0.25 mg/kg/h i.v. (group 1...

journal_title：Journal of cardiovascular pharmacology

authors： Daniell HB,Carson RR,Ballard KD,Thomas GR,Privitera PJ

更新日期：1984-11-01 00:00:00

abstract：:Traditionally, antihypertensive medications were used in few children or adolescents, usually just those with underlying renal or other organ system disease. However, with recent data suggesting that the incidence of primary hypertension may be increasing in the young, it is possible that more children and adolescents...

journal_title：Journal of cardiovascular pharmacology

authors： Flynn JT

更新日期：2011-08-01 00:00:00

abstract：:Gangliosides, sialic acid-containing glycosphigolipids, are localized mostly to the outer leaflet of the lipid bilayer in the plasma membrane, particularly in brain. Gangliosides reduce edema formation, restore glucose metabolism, and increase cerebral blood flow after focal ischemia in the rat brain. We wished to det...

journal_title：Journal of cardiovascular pharmacology

authors： Maulik N,Das DK,Gogineni M,Cordis GA,Avrova N,Denisova N

更新日期：1993-07-01 00:00:00

abstract：:Intravenous (i.v.) administration of bromocriptine (150 micrograms/kg) in conscious normotensive rats with chronic spinal cord transection (at T5-T7), pretreated or not with i.v. propranolol (0.5 mg/kg), induced significant decreases in mean arterial blood pressure (MAP) which were greater and longer lasting than thos...

journal_title：Journal of cardiovascular pharmacology

authors： Lahlou S,Demenge P

更新日期：1992-05-01 00:00:00

abstract：:As a receptor for transforming growth factor-β, nodal and activin, activin receptor-like kinase 7 (ALK7) previously acts as a suppressor of tumorigenesis and metastasis, which has emerged to play a key role in cardiovascular diseases. However, the potential effect and molecular mechanism of ALK7 on vascular smooth mus...

journal_title：Journal of cardiovascular pharmacology

authors： Gong FH,Cheng WL,Zhang Q,Chen XL,Cao JL,Yang T,Song WH,Zhao F

更新日期：2020-08-01 00:00:00

abstract：:To clarify the characteristics of KC-399, a newly synthesized potassium channel opener, we investigated the effects of KC-399 and lemakalim on the contractions induced by norepinephrine (NE 1 microM) and K+ (30 and 90 mM) and on 86Rb efflux in rat thoracic aorta. KC-399 (0.01-10 nM) and lemakalim (0.001-10 microM) ind...

journal_title：Journal of cardiovascular pharmacology

authors： Tamura K,Suzuki Y,Yoshida S,Nabata H

更新日期：1994-02-01 00:00:00

abstract：:Several 3,5-pyridinedicarboxylic acid [4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-] esters, which are analogs to felodipine, were synthesized and tested for peroral activity and vascular selectivity. Structure-activity relationships demonstrate that felodipine has biological properties (selectivity and oral activ...

journal_title：Journal of cardiovascular pharmacology

authors： Berntsson P,Johansson E,Westerlund C

更新日期：1987-01-01 00:00:00

abstract：:The exercise response to a single oral dose (25 mg) of a new beta-blocking agent that also has potent vasodilating properties, carvedilol, was assessed in 15 patients with stable exertional angina, positive exercise tests (greater than or equal to 1 mm ST depression) and coronary artery disease. A placebo-controlled, ...

journal_title：Journal of cardiovascular pharmacology

authors： Kaski JC,Rodriguez-Plaza L,Brown J,Maseri A

更新日期：1987-01-01 00:00:00

abstract：:Intravenous diltiazem (10-300 micrograms/kg), verapamil (10-300 micrograms/kg), nifedipine (1-100 micrograms/kg) and nicardipine (1-100 micrograms/kg) inhibited the tachycardia caused by cardiac sympathetic nerve stimulation (SNS, 0.5-4 Hz) in decentralized hearts of anesthetized dogs. The dose range of each drug requ...

journal_title：Journal of cardiovascular pharmacology

authors： Satoh E,Mukaiyama O,Kimura T,Satoh S

更新日期：1990-10-01 00:00:00

abstract：:T89 (Dantonic) is a modern herbal medicine currently used in Chinese hospitals for the management of ischemic heart disease. This dose-escalation clinical trial aims to assess tolerability of Western people to T89. Healthy Australian adults of non-Asian background orally took a single dosage of 6, 8, 10, 12, 13, 14, 1...

journal_title：Journal of cardiovascular pharmacology

authors： Ling S,Luo RZ,Nheu L,Guo ZX,Sun H,Komesaroff PA

更新日期：2012-12-01 00:00:00

abstract：:The vulnerable period (VP) is an interval of time during the cardiac cycle within which premature stimulation may lead to trains of responses (one: many stimulus-response coupling). Although the VP parallels the recovery of sodium channel availability, modulators of its boundaries remain unclear. Numerical studies of ...

journal_title：Journal of cardiovascular pharmacology

authors： Nesterenko VV,Lastra AA,Rosenshtraukh LV,Starmer CF

更新日期：1992-05-01 00:00:00

abstract：:The disposition of amlodipine, a new calcium-channel blocker with a slow onset and long duration of action, has been investigated in humans and in the animal species used in the evaluation of drug efficacy and safety. Pharmacokinetic studies were conducted with nonlabeled drug using specific high-pressure liquid chrom...

journal_title：Journal of cardiovascular pharmacology

authors： Stopher DA,Beresford AP,Macrae PV,Humphrey MJ

更新日期：1988-01-01 00:00:00

abstract：:Isolated perfused rat kidney was used to examine the possible mechanisms involved in the hypotensive/vasodilator actions of cryptolepine. In kidneys preconstricted by phenylephrine (PE 5-7.5 x 10(-7) M), cryptolepine at bolus doses of 2.5, 5, and 10 micrograms elicited dose-dependent reductions in perfusion pressure b...

journal_title：Journal of cardiovascular pharmacology

authors： Oyekan AO

更新日期：1994-04-01 00:00:00

abstract：:The aim of the present work was to examine the effects of 4'-N-benzoyl staurosporine (CGP 41251), a protein kinase C inhibitor with broad antiproliferative activity in many cell lines, on the rat isolated heart contractility under normoxic and hypoxic conditions. Additionally, we examined the effects of CGP 41251, WB-...

journal_title：Journal of cardiovascular pharmacology

authors： Kocic I,Dworakowska D,Dworakowski R,Petrusewicz J

更新日期：2001-06-01 00:00:00

abstract：:The relationship between arterial pressure and the rate of Na+ excretion is regulated by a number of mechanisms- some well known, some newly discovered, and probably some yet to be discovered. These mechanisms affect either the amount of Na+ filtered at the glomerulus or its rate of reabsorption from the proximal or d...

journal_title：Journal of cardiovascular pharmacology

authors： Anderson WP,Evans RG,Malpas SC

更新日期：1995-01-01 00:00:00

abstract：:The electrophysiological effects of 0.2 mg/kg of intravenously administered verapamil (mean plasma level, 51.3 ng/ml) were evaluated using intracardiac recordings and electrical stimulation in 10 patients with the concealed or manifest Wolff-Parkinson-White syndrome. Verapamil produced a minimal effect on both the ant...

journal_title：Journal of cardiovascular pharmacology

authors： Matsuyama E,Konishi T,Okazaki H,Matsuda H,Kawai C

更新日期：1981-01-01 00:00:00

abstract：:Twenty-four-hour urinary sodium excretion and plasma renin activity were monitored in 36 patients receiving bendrofluazide as sole antihypertensive therapy. There was no increase in urinary sodium output compared with pretreatment values during a 2-year period, and there is therefore no evidence that an increase in sa...

journal_title：Journal of cardiovascular pharmacology

authors： Swales JD,Bing RF,Swart S,Thurston H

更新日期：1984-01-01 00:00:00

abstract：:The purpose of the present study was to assess the effects of chronic treatment with an orally active chymase inhibitor, 4-[1-(naphthylmethyl)benzimidazol-2-ylthio]butanoic acid (TEI-E548), in a hamster myocardial infarction model. In the first experiment, after confirming the biochemical inhibitory action of TEI-E548...

journal_title：Journal of cardiovascular pharmacology

authors： Hoshino F,Urata H,Inoue Y,Saito Y,Yahiro E,Ideishi M,Arakawa K,Saku K

更新日期：2003-01-01 00:00:00

abstract：:Epoxyeicosatrienoic acids, substrates for soluble epoxide hydrolase (sEH), exhibit vasodilatory and antihypertrophic activities. Inhibitors of sEH might therefore hold promise as heart failure therapeutics. We examined the ability of sEH inhibitors GSK2188931 and GSK2256294 to modulate cardiac hypertrophy, fibrosis, a...

journal_title：Journal of cardiovascular pharmacology

authors： Morgan LA,Olzinski AR,Upson JJ,Zhao S,Wang T,Eisennagel SH,Hoang B,Tunstead JR,Marino JP Jr,Willette RN,Jucker BM,Behm DJ

更新日期：2013-04-01 00:00:00

abstract：:Lactoferrin (LF) exerts a variety of biological effects, including the promotion of angiogenesis by increasing the expression of angiogenesis-related genes and reducing blood pressure via a nitric oxide-dependent mechanism. In this study, we investigated the effects of LF on angiogenesis using C57BL/6J mice that recei...

journal_title：Journal of cardiovascular pharmacology

authors： Ikeda Y,Tajima S,Izawa-Ishizawa Y,Kihira Y,Ishizawa K,Yoshida S,Aihara K,Tsuchiya K,Tamaki T

更新日期：2013-05-01 00:00:00

abstract：:Carthamin yellow (CY) is a flavonoid compound isolated from safflower, which is widely used clinically in China. It has various pharmacological effects including promoting blood circulation to remove blood stasis and alleviating pain. Ischemic heart disease is one of the main culprits of illness and death. Here, in th...

journal_title：Journal of cardiovascular pharmacology

authors： Lu QY,Ma JQ,Duan YY,Sun Y,Yu S,Li B,Zhang GM

更新日期：2019-09-01 00:00:00